Praxis Precision Medicines snapshot: what recent returns say about the stock

Praxis Precision Medicines (PRAX) has drawn investor attention after a period where the stock is up about 9% over the past month and about 4% over the past 3 months.

Those moves come alongside a reported 1 year total return of about 833% and a market value near US$9.6b, which has put this clinical stage CNS-focused biopharmaceutical company firmly on many growth oriented watchlists.

With a 1 day share price return of 0.87%, a 7 day share price return of 2.40% and a year to date share price return of 20.88%, the stock’s very large 1 year total shareholder return suggests momentum has been building over a longer period rather than just in recent weeks.

If rapid gains in a single biotech catch your eye, it can be helpful to see what else is moving. You could start with 33 healthcare AI stocks

With Praxis trading at about an 88% discount to one set of analyst and intrinsic value estimates, yet still reporting losses and no revenue, the key issue is whether this gap signals a potential opportunity or reflects markets already pricing in expectations for the company.

Most Popular Narrative: 23% Undervalued

Praxis Precision Medicines closed at about $346, while the most followed narrative points to a fair value near $449, which is a sizeable valuation gap for a pre revenue biotech.

Multiple late stage epilepsy programs, including vormatrigine and relutrigine with breakthrough designation in severe genetic epilepsies, create a portfolio effect in a growing CNS innovation cycle. This increases the probability of multiple approvals and a step change in total company earnings over the back half of the decade.

Analysts are relying on steep revenue ramps, a sharp swing from heavy losses to profitability, and a rich future earnings multiple to support that price target. Want to see exactly how those moving parts fit together in the full narrative and how sensitive the fair value is to those assumptions.

Result: Fair Value of $449 (UNDERVALUED)

However, this upbeat story can be knocked off course if pivotal epilepsy trials disappoint or if competing treatments limit Praxis’s ability to convert clinical data into broad adoption.

Next Steps

Given the mix of optimism around potential rewards and concern about key risks, it makes sense to promptly review the underlying data and reach your own view using the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Praxis has you thinking more broadly about opportunities, do not stop here. Use focused screens to quickly spot other stocks that could suit your approach.

• Target potential mispricings by scanning for companies that combine quality metrics with attractive valuations using the 46 high quality undervalued stocks
• Strengthen your income watchlist by zeroing in on resilient payers through the 14 dividend fortresses
• Prioritise financial resilience by filtering for companies with robust balance sheets via the solid balance sheet and fundamentals stocks screener (46 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.